Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 28;10:3684. doi: 10.1038/s41598-020-60680-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

P334 accelerates generation of human iPSCs from human fibroblasts during the reprogramming process. (A) Schematic diagram describing the main theme and experimental procedure of human dermal papilla (HDP) reprogramming. (B) Representative images of the generated human iPSCs (0, 5, 15 and 20 days after lentivirus infection) in DMSO control and P334 treated. The bottom row representing the OCT3/4 and NANOG positive immuno fluorescence images in DMSO control and P334 treated batches. (Scale bar: 30 um) (C) The bar graph representing the number of human iPSCs in DMSO control and P334 treated batches at 0, 5, 15 and 20 days after lentivirus infection (data represent mean ± SEM. *p < 0.05, **p < 0.01). (D) The bar graph representing number of OCT3/4 and NANOG immuno positive colonies in DMSO control and P334 treated batches at 20 days after lentivirus infection (data represent mean ± SEM. **p < 0.01). (E) QRT-PCR analysis of pluripotent markers OCT3/4, SOX2, ESRRB, SSEA1 and CDH1 in hOSKM-infected HDP with and without P334 treated at 20 days after lentivirus infection (data represent mean ± SEM. *p < 0.05, **p < 0.01). (F) QRT-PCR analysis of MET genes (CDH1 and OCCLUDIN) in OSKM-infected HDP with P334 treated at 20 days after lentivirus infection (data represent mean ± SEM. **p < 0.01).